News

[Hørsholm, Denmark – December 03, 2024] – Contera Pharma A/S, a clinical-stage biotech company pioneering treatments for neurological disorders, is proud to announce the appointment of new members to its Board of Directors. These strategic additions reflect Contera Pharma’s commitment to advancing innovative patient-centered therapies. Dr. Mahmoud Mahmoudian, FRS Dr. Mahmoud Mahmoudian brings over 25 […]

Contera Pharma A/S, a clinical-stage biotech company pioneering innovative treatments for neurological disorders, has announced the dosing of the first patient in a Phase 1b pharmacoscintigraphic study evaluating CP-012. This novel delayed-release, dual-pulse levodopa/carbidopa tablet is designed to address the distinct challenges of nocturnal immobility and early morning akinesia in Parkinson’s disease (PD) patients. These […]

Notice of Dissolution and Filing of Claims Contera Pharma A/S has decided to close the branch office in Korea and consolidate all activities in the Headquarter in Denmark. The formal notice of dissolution and filing of claims can be found below. The Company has resolved to dissolve at the Board of Directors meeting in 2024/ […]

Notice of Dissolution and Filing of Claims Contera Pharma A/S has decided to close the branch office in Korea and consolidate all activities in the Headquarter in Denmark. The formal notice of dissolution and filing of claims can be found below. The Company has resolved to dissolve at the Board of Directors meeting in 2024/ […]

[Hørsholm, September 6, 2024] – Contera Pharma A/S, a clinical-stage biotech company developing innovative therapies to treat neurological disorders, is pleased to announce key changes to its leadership team. These strategic appointments underscore the company’s commitment to advancing clinical excellence, financial integrity, and scientific innovation. Contera Pharma has welcomed Dr. Anne Birk Østerskov as Chief […]

[Hørsholm, May 21st, 2024] – Contera Pharma A/S, a biotech company developing innovative therapies to treat neurological disorders, announce topline results from the ASTORIA Phase IIb trial of JM-010 in people suffering from dyskinesia in Parkinson´s disease.  The main objectives of the trial were to investigate efficacy and safety of two doses of JM-010, compared […]